GSK Avamys nasal spray

Avamys is a prescription-only nasal spray containing fluticasone furoate, used for the treatment of allergic rhinitis symptoms. Developed and marketed by GlaxoSmithKline (GSK), it features an ergonomically designed device for precise delivery.

Originally launched by GlaxoSmithKline, a British global pharmaceutical giant formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, the brand is part of GSK’s specialty respiratory portfolio. Manufacturing of Avamys occurs across several global sites to ensure supply for international markets.

As of 2026, the ultimate owner remains GSK plc, headquartered in London, United Kingdom. The company continues to operate as a specialized biopharmaceutical innovator following the demerger of its consumer healthcare business, Haleon, in 2022.